Rye Brook Capital’s VanEck Pharmaceutical ETF PPH Stock Holding History

Rye Brook Capital’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.36M	Buy	+67,330	New	+$6.97M	5.16%	5

Other funds holding PPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return

AWC

Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

Rye Brook Capital's PPH Position: Q2 2026 in Review

Rye Brook Capital opened a new position in VanEck Pharmaceutical ETF (PPH) in Q2 2026: 67,330 shares worth $7.36M. The stake represents 5.16% of the portfolio and ranks #5 among its holdings.

148 funds tracked by Wall St. Rank hold PPH as of Q2 2026.

Rye Brook Capital held 67,330 shares of VanEck Pharmaceutical ETF worth $7.36M as of Q2 2026.
VanEck Pharmaceutical ETF was a new Rye Brook Capital position in Q2 2026.
VanEck Pharmaceutical ETF made up 5.16% of Rye Brook Capital's portfolio in Q2 2026, its #5 holding.
148 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2026.

Based on Rye Brook Capital's 13F filing for Q2 2026, filed 20 Jul 2026.